This could be because we use these drugs only to treat infections with MDR bacteria as a last-line therapy in our setting, and because of their infrequent use, the emergence and dissemination of penicillins with beta-lactamase inhibitors- and aminoglycoside-resistant genes are minimal, which restrains the emergence of resistance to these antibiotics. This evidence concerns the gene LACTB and infection.